Mark C Noe
Overview
Explore the profile of Mark C Noe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schiemer J, Horst R, Meng Y, Montgomery J, Xu Y, Feng X, et al.
Nat Chem Biol
. 2020 Nov;
17(2):152-160.
PMID: 33199914
Heterobifunctional chimeric degraders are a class of ligands that recruit target proteins to E3 ubiquitin ligases to drive compound-dependent protein degradation. Advancing from initial chemical tools, protein degraders represent a...
2.
DiRico K, Hua W, Liu C, Tucker J, Ratnayake A, Flanagan M, et al.
ACS Med Chem Lett
. 2020 Jun;
11(6):1101-1110.
PMID: 32550988
High-throughput experimentation (HTE) has emerged as an important tool in drug discovery, providing a platform for preparing large compound libraries and enabling swift reaction screening over wide-ranging conditions. Recent advances...
3.
Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J, et al.
Proc Natl Acad Sci U S A
. 2018 Jul;
115(31):E7285-E7292.
PMID: 30012605
Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that simultaneously bind to a target protein and an E3 ligase, thereby leading to ubiquitination and subsequent degradation of the target. They...
4.
Che Y, Gilbert A, Shanmugasundaram V, Noe M
Bioorg Med Chem Lett
. 2018 Jul;
28(15):2585-2592.
PMID: 29980357
The drugable proteome is limited by the number of functional binding sites that can bind small molecules and respond with a therapeutic effect. Orthosteric and allosteric modulators of enzyme function...
5.
Flanagan M, Abramite J, Anderson D, Aulabaugh A, Dahal U, Gilbert A, et al.
J Med Chem
. 2014 Nov;
57(23):10072-9.
PMID: 25375838
Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymatic activity until protein resynthesis can occur,...
6.
Flanagan M, Brickner S, Lall M, Casavant J, Deschenes L, Finegan S, et al.
ACS Med Chem Lett
. 2014 Jun;
2(5):385-90.
PMID: 24900319
A novel series of monocarbam compounds exhibiting promising antibacterial activity against multidrug resistant Gram-negative microorganisms is reported, along with the synthesis of one such molecule MC-1 (1). Also reported are...
7.
Brown M, Mitton-Fry M, Arcari J, Barham R, Casavant J, Gerstenberger B, et al.
J Med Chem
. 2013 Jun;
56(13):5541-52.
PMID: 23755848
Herein we describe the structure-aided design and synthesis of a series of pyridone-conjugated monobactam analogues with in vitro antibacterial activity against clinically relevant Gram-negative species including Pseudomonas aeruginosa , Klebsiella...
8.
Magee T, Brown M, Starr J, Ackley D, Abramite J, Aubrecht J, et al.
J Med Chem
. 2013 Jun;
56(12):5079-93.
PMID: 23735048
We report novel polymyxin analogues with improved antibacterial in vitro potency against polymyxin resistant recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa . In addition, a human renal cell...
9.
McAllister L, Montgomery J, Abramite J, Reilly U, Brown M, Chen J, et al.
Bioorg Med Chem Lett
. 2012 Oct;
22(22):6832-8.
PMID: 23046961
The synthesis and antibacterial activity of heterocyclic methylsulfone hydroxamates is presented. Compounds in this series are potent inhibitors of the LpxC enzyme, a key enzyme involved in the production of...
10.
Mitton-Fry M, Arcari J, Brown M, Casavant J, Finegan S, Flanagan M, et al.
Bioorg Med Chem Lett
. 2012 Aug;
22(18):5989-94.
PMID: 22892121
Novel siderophore-linked monobactams with in vitro and in vivo anti-microbial activity against MDR Gram-negative pathogens are described.